Z Adam, D Zeman, A Chodacki, L Pour, T Horváth, P Benda, Z Adamová, M Krejčí, M Tomíška, I Boichuk, Z Král
BACKGROUND: Idiopathic multicentric Castleman disease (iMCD) is characterized by constitutional symptoms, enlarged lymph nodes and laboratory test abnormalities, which are primarily related to the overproduction of interleukin-6 (IL-6). This form (iMCD) was treated earlier with cytostatics used for lymphoma, later with bio-logic therapy as rituximab, immunodulatory drugs and proteasome inhibitors, and in the last years with an anti-IL-6 antibody, siltuximab. Siltuximab is a human-mouse chimeric immunoglobulin G1k monoclonal antibody against human IL-6 approved in the European Union for the treatment of iMCD...
2023: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti